Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes Indeed it does...🥳
Looking good georgie18 🥳
$SGMO
SGMO...9095...HOD...🥳
georgie18
Member Level
Re: None
Friday, August 23, 2024 7:50:53 AM
Post#
811
of 814
SGMO...856...Looking to scale in for another entry...Last move .30 range to $1.20 range...Owned SGMO...from .30 to .80 range...on the $1.20 move...Looking for $1.48 Breakout on next move...🥳
Except when it went from $1.50 to .30...lol...🥳
It has been very predictable so far
SGMO...856...Looking to scale in for another entry...Last move .30 range to $1.20 range...Owned SGMO...from .30 to .80 range...on the $1.20 move...Looking for $1.48 Breakout on next move...🥳
Higher high and higher low,reversal sign last 2 days,might be up up up time
Exactly. We can see where it's going, just needs that $ to land in the Revenue column.
And/or for another agreement to be announced.
When real $$$ starts getting reported by the company ... Look Out ...
I think it will definitely be there one day soon. (within the next 6 mths.)
Looking good! 🚀
$SGMO
"HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics ( SGMO ) with a Buy and maintains $5 price target. ."
Came across the wire just now on Fidelity ... THAT would be nice ...
Patiently waiting. Worse case scenario, you have to jump back in on the fly and miss 10-20 points.
JMO
Trendzone.. I 100% agree with your statement. Lets hope there is a great "Load Zone" opportunity for everyone within the next couple of weeks. Have a great day!
It would be awesome if it was to drop to below $0.60,that would be a great load zone, there is some kind of orchestrated grind down programs in place for more than the past week,most likely being run by a group of very corrupt hedge funds, probably still holding large naked short positions that won't cover until there is a high volume breakdown and flush out so the scm bags can close them out,the pricks squash every uptick with naked shorting the bid right back down, probably not a good buy until there is a big volume flush with a good size downstick,and a nice little bounce,of course some kind of big news could change all that in a hurry,and burn the crap out of the shorting criminals.
I believe the analyst from Barclays Mrs Gena Wang is correct regarding her SGMO buy rating and price target of $3.00. I personally will commit to a small position at .75 this week and I will be purchasing more if it hits .65 and so on.
SLOW bleed ... Nothing fatal ... Healthy retrace looks like to me .
What doesn't kill you makes you stronger ... right ???
Thank you…🥳
You too g18!!!
SGMO...88... https://schrts.co/ktDFQVTr ...Bullish Doji Star Reversal Pattern to the Upside on the close...Watching to see a confirmation Candle on Monday...20MA at 81...wanna see if the pattern is effective and holds above the 20ma...🥳
NSDQ was really soaking them up at the close.
More churning , building a base perhaps ...
Enjoy the weekend >> M
Inst. Holdings dropped by approx. 9%. They are not showing any transactions, nor are they showing any increase in OS shares?
Will be looking for a filing or two.
https://www.nasdaq.com/market-activity/stocks/sgmo/institutional-holdings?page=5&rows_per_page=10
Friday...Weekly overbought
ARCA and the crew are loading up the Ask.
SGMO: Volume picking up into the close.
Yep that would be nice molee, just crush $1.20-$1.25, then create that as support then on to $1.48!and above !!!
Now we're moving UP . Break resistance this time ???
Up 5% pre-market, this week will see $1.20+++
Sangamo will be massively green this week!
- Pfizer clinical trials with great news and sweetheart benchmark payments to commence for SGMO
- massive Genentech deal for $50,000,000 is benchmark payments
- analyst upgrades, x8 analysts averaged have raised to 12 month target to $3.80
:)
$$$
I have the same vision.. I see a pull back to .85 especially with next weeks reporting.
New 52 week high imminent! $1.48 plus!!!! That’s my target. Genentech capsid delivery deal is kicking in $50,000,000 to Sangamo plus more milestone payments. And guess what the technology is not exclusive other majors will partner with $SGMO this is just the beginning!
Monday Sangamo should have a great start to the week. Easily regain Friday’s $1.11 HOD as buying will be the trend on markets after last weeks temporary sell off.
Combine this with the Pfizer clinical trials amazing update, the cash deal for capsid deliveries with Roche’s Genentech will more capsid deals with more partners to be announced, and the analyst upgrades commented on Friday, more analyst upgrades throughout the week, SGMO has the potential to really rise above the 52 week high of $1.48 near term.
STRONG and reliable BUY!!!
:)
$$$
I agree with your statement 100% molee, hope you have a great weekend!!!
Thank you...🥳
Yes , enjoy the weekend all . I like how they closed it above a buck .
I , for one , always appreciate having at least one "chartist" on the board .
The more information at my disposal the better , I think . ..
Did anyone check out the transcript that I posted the other day ?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174883404
Followers
|
84
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
818
|
Created
|
09/09/04
|
Type
|
Free
|
Moderators |
http://www.sangamo.com/index.php
http://finance.yahoo.com/q/ks?s=SGMO+Key+Statistics
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company?s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington?s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |